12.47
0.02 (0.16%)
Market Trend
Short Term | Medium Term | ||
Industry | Health Information Services (US) | Bearish | Bearish |
Health Information Services (Global) | Bearish | Bearish | |
Stock | R1 RCM Inc. | Bearish | Bearish |
Analyst Consensus
8 Buy, 3 Hold
Avg. Price @ Call: 13.37
R1 RCM Inc is a provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. Its services help healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for the customers, Its service offering consists of end-to-end RCM services for health systems, hospitals, and physician groups that provide comprehensive revenue cycle infrastructure to providers, including all revenue cycle personnel, technology solutions, and process workflow. The majority of the revenue comes from the operating fees received. |
|
Sector | Healthcare |
Industry | Health Information Services |
Investment Style | Small Growth |
Ownership
Name | Date | Shares Held |
---|---|---|
New Mountain Capital, L.L.C. | 31 Dec 2023 | 94,408,780 |
Sachem Head Capital Management Lp | 31 Dec 2023 | 9,605,000 |
52 Weeks Range |
8.87 - 18.71
|
|
Price Target Range | ||
High | 20.00 (Cantor Fitzgerald, 60.38%) | Buy |
Median | 16.00 (28.31%) | |
Low | 14.00 (Leerink Partners, 12.27%) | Buy |
14.00 (Barclays, 12.27%) | Hold | |
Average | 16.27 (30.50%) | |
Total | 8 Buy, 3 Hold |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Canaccord Genuity | 09 May 2024 | 15.00 (20.29%) | Buy | 12.27 |
20 Mar 2024 | 16.00 (28.31%) | Buy | 13.15 | |
Cantor Fitzgerald | 10 Apr 2024 | 20.00 (60.38%) | Buy | 12.70 |
05 Mar 2024 | 20.00 (60.38%) | Buy | 13.97 | |
Guggenheim | 05 Apr 2024 | 15.00 (20.29%) | Buy | 12.47 |
Truist Securities | 01 Apr 2024 | 16.00 (28.31%) | Hold | 12.56 |
05 Mar 2024 | 16.00 (28.31%) | Hold | 13.97 | |
Morgan Stanley | 26 Mar 2024 | 17.00 (36.33%) | Buy | 13.00 |
Citigroup | 20 Mar 2024 | 16.00 (28.31%) | Buy | 13.15 |
01 Mar 2024 | 16.00 (28.31%) | Buy | 14.00 | |
RBC Capital | 07 Mar 2024 | 19.00 (52.37%) | Buy | 14.19 |
Keybanc | 29 Feb 2024 | 17.00 (36.33%) | Buy | 14.05 |
Barclays | 28 Feb 2024 | 14.00 (12.27%) | Hold | 14.39 |
Evercore ISI Group | 28 Feb 2024 | 16.00 (28.31%) | Hold | 14.39 |
Leerink Partners | 26 Feb 2024 | 14.00 (12.27%) | Buy | 13.89 |
No data within this time range.
Date | Type | Details |
---|---|---|
08 May 2024 | Announcement | R1 RCM Reports First Quarter 2024 Results |
30 Apr 2024 | Announcement | R1 RCM to Present at the 2024 Bank of America Securities Health Care Conference |
01 Apr 2024 | Announcement | R1 RCM to Release First Quarter 2024 Results on May 8, 2024 |
27 Mar 2024 | Announcement | R1 Releases Fourth Annual Environmental, Social and Governance (ESG) Report |
11 Mar 2024 | Announcement | R1 RCM Forms Special Committee to Evaluate Strategic Alternatives |
27 Feb 2024 | Announcement | R1 RCM Reports Fourth Quarter and Full Year 2023 Results |
26 Feb 2024 | Announcement | Coliseum Capital Issues Open Letter to Board of R1 RCM on Offer by New Mountain to Acquire the Company for $13.75 Per Share |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |